CAS: 866460-33-5 - Setipiprant
Formel:C24H19FN2O3
InChl:InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)
InChI Key:InChIKey=IHAXLPDVOWLUOS-UHFFFAOYSA-N
SMILES:O=C(O)CN1C=2C=CC(F)=CC2C3=C1CCN(C(=O)C4=CC=CC=5C=CC=CC54)C3
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | 2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid REF: IN-DA00GU6HCAS: 866460-33-5 | % | 22,00 €~120,00 € | Di 21 Jan 25 |
 | Setipiprant REF: TM-T3520CAS: 866460-33-5 | 99.16% | 35,00 €~260,00 € | Mo 27 Jan 25 |
 | Setipiprant(ACT-129968) REF: 3D-RJB46033CAS: 866460-33-5 | Min. 95% | Nachfragen | Mo 03 Mär 25 |
![2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid](https://static.cymitquimica.com/products/IN/thumb/DA00GU6H.jpg)
2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
CAS:866460-33-5
Formel:
C24H19FN2O3
Reinheit:
%
Farbe und Form:
Solid
Molekulargewicht:
402.4177
Ref: IN-DA00GU6H
| 5mg | 22,00 € | ||
| 25mg | 39,00 € | ||
| 100mg | 67,00 € | ||
| 250mg | 120,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 21. Januar 2025
Setipiprant
CAS:866460-33-5
Setipiprant (ACT-129968) is an oral CRTH2 antagonist for asthma/allergy, targeting PGD2-induced inflammation (IC50: 6.0 nM).
Formel:
C24H19FN2O3
Reinheit:
99.16%
Farbe und Form:
Solid
Molekulargewicht:
402.42
Ref: TM-T3520
| 10mg | 46,00 € | ||
| 25mg | 78,00 € | ||
| 50mg | 114,00 € | ||
| 100mg | 176,00 € | ||
| 200mg | 260,00 € | ||
| 1mL*10mM (DMSO) | 36,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Montag 27. Januar 2025
Setipiprant(ACT-129968)
CAS:866460-33-5
Setipiprant is a CRTH2-selective antagonist, which has been shown to be effective in reducing the …
Formel:
C24H19FN2O3
Reinheit:
Min. 95%
Molekulargewicht:
402.42 g/mol
Ref: 3D-RJB46033
| 100mg | 989,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Montag 3. März 2025
